Feb. 11, 2013
has released the February issue of
. The issue features a comprehensive review of ALS, and the continuing but frustrating search for a genuinely useful treatment for the treatment of this devastating illness.
"Just as Alzheimer's slowly erases memory and personality, ALS gradually destroys muscle control, leaving patients almost invariably doomed to death from respiratory failure. The Phase III failure of
's dexpramipexole has provided yet another reminder of how difficult it has been to achieve any headway against ALS," said
, Ph.D., editor and publisher of NeuroPerspective.
The 21-page issue includes:
An overview of the pathophysiology of ALS; a reconsideration of SOD1 anomalies in recapitulating phenotype rather than genotype; and the growing interest in therapeutic approaches that address immunoreactive and inflammatory factors.
) Programs covered in the review include those from
Isis Pharmaceuticals, Neuraltus, Newron, NeuralStem, BrainStorm Cell Therapeutics, Cambria Pharmaceuticals, Regenesance, Amorfix, KineMed
plus many others. The prominent role of
in ALS research is noted, as is its intriguing program assessing the potential value of
' Gilenya as an ALS therapeutic.
Other coverage and commentary in the February issue includes:
- Genentech's licensing of the Afraxis PAK program
- Executive Turbulence at AstraZeneca and EnVivo Pharmaceuticals
- Teva and Tire Irons: The Risk of Going MAD
A brief summary review of
, developing therapeutics for disorders associated with complement activation.
The February issue of
is being made available as a